Evidence map›Paper›PMID 24966896›Full record

ArticleInternational journal of clinical and experimental pathology2014

miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer.

Pablo Letelier, Patricia García, Pamela Leal, Héctor Álvarez, Carmen Ili, Jaime López, Jonathan Castillo, Priscilla Brebi, Juan Carlos Roa

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Frontiers in genetics · 2023
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Overview of current targeted therapy in gallbladder cancer.Signal transduction and targeted therapy · 2020
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Pablo LetelierDepartment of Pathology, School of Medicine, Scientific and Technological Bioresource Nucleus (BIOREN-CEGIN), Universidad de La Frontera Manuel Montt 112, Postal Code 4781176, Temuco, Chile ; School of Health Sciences, Universidad Católica de Temuco Manuel Montt 56, Postal Code 4813302, Temuco, Chile.
Patricia GarcíaDepartment of Pathology, School of Medicine, Center of Translational Research in Oncology, Pontificia Universidad Católica de Chile Portugal 61, Postal Code 8330034, Santiago, Chile.
Pamela LealDepartment of Pathology, School of Medicine, Scientific and Technological Bioresource Nucleus (BIOREN-CEGIN), Universidad de La Frontera Manuel Montt 112, Postal Code 4781176, Temuco, Chile.
Héctor ÁlvarezMD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Houston, TX 77030, USA.
Carmen IliDepartment of Pathology, School of Medicine, Scientific and Technological Bioresource Nucleus (BIOREN-CEGIN), Universidad de La Frontera Manuel Montt 112, Postal Code 4781176, Temuco, Chile.
Jaime LópezDepartment of Pathology, School of Medicine, Scientific and Technological Bioresource Nucleus (BIOREN-CEGIN), Universidad de La Frontera Manuel Montt 112, Postal Code 4781176, Temuco, Chile.
Jonathan CastilloDepartment of Pathology, School of Medicine, Scientific and Technological Bioresource Nucleus (BIOREN-CEGIN), Universidad de La Frontera Manuel Montt 112, Postal Code 4781176, Temuco, Chile.
Priscilla BrebiDepartment of Pathology, School of Medicine, Scientific and Technological Bioresource Nucleus (BIOREN-CEGIN), Universidad de La Frontera Manuel Montt 112, Postal Code 4781176, Temuco, Chile.
Juan Carlos RoaDepartment of Pathology, School of Medicine, Center of Translational Research in Oncology, Pontificia Universidad Católica de Chile Portugal 61, Postal Code 8330034, Santiago, Chile.
Universidad de La Frontera · CLPontificia Universidad Católica de Chile · CLThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of miRNA-based therapeutics represents a new strategy in cancer treatment. The objectives of this study were to evaluate the differential expression of microRNAs in gallbladder cancer (GBC) and to assess the functional role of miR-1 and miR-145 in GBC cell behavior. A profile of miRNA expression was determined using DharmaconTM microarray technology. Differential expression of five microRNAs was validated by TaqMan reverse transcription quantitative-PCR in a separate cohort of 8 tumors and 3 non-cancerous samples. Then, we explored the functional role of miR-1 and miR-145 in tumor cell behavior by ectopic in vitro expression in the GBC NOZ cell line. Several miRNAs were found to be aberrantly expressed in GBC; most of these showed a significantly decreased expression compared to non-neoplastic tissues (Q value<0.05). The differential expression of 7 selected miRNAs was confirmed by real time PCR. Pathway enrichment analysis revealed that the most deregulated miRNAs (miR-1, miR-133, miR-143 and miR-145) collectively targeted a number of genes belonging to signaling pathways such as TGF-β, ErbB3, WNT and VEGF, and those regulating cell motility or adhesion. The ectopic expression of miR-1 and miR-145 in NOZ cells significantly inhibited cell viability and colony formation (P<0.01) and reduced gene expression of VEGF-A and AXL. This study represents the first investigation of the miRNA expression profile in gallbladder cancer, and our findings showed that several miRNAs are deregulated in this neoplasm. In vitro functional assays suggest that miR-1 and miR-145 act as tumor suppressor microRNAs in GBC.

Indexed as

Gene Expression Regulation, NeoplasticAxl Receptor Tyrosine KinaseCell Line, TumorCell ProliferationCell SurvivalCluster AnalysisGallbladder NeoplasmsGene Expression ProfilingGene Regulatory NetworksHumansMicroRNAsOligonucleotide Array Sequence AnalysisProto-Oncogene ProteinsReal-Time Polymerase Chain ReactionReceptor Protein-Tyrosine KinasesReproducibility of ResultsAXL protein, humanAxl Receptor Tyrosine KinaseMicroRNAsMIRN145 microRNA, humanMIRN1 microRNA, humanProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesVascular Endothelial Growth Factor AVEGFA protein, humanGallbladder cancermicroRNAsmiR-1miR-145NOZ cells

Identifiers

PMID24966896
PMCPMC4069933
OpenAlexW2296419505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.